12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TMC435: Additional Phase IIb data

Additional data from the double-blind Phase IIb ASPIRE (C206) trial in 462 treatment-experienced patients with chronic HCV genotype 1 infection showed that 70%, 66% and 61% of patients receiving once-daily 100 mg TMC435 for 12, 24 or 48 weeks plus standard of care (SOC; peginterferon alfa-2a and ribavirin), respectively, achieved an SVR, defined as undetectable HCV RNA levels (<25 IU/mL), 24 weeks after the end of treatment, the primary endpoint, vs. 23% for placebo plus...

Read the full 352 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >